<- Go Home
Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Market Cap
CHF 19.7B
Volume
1.7M
Cash and Equivalents
CHF 701.0M
EBITDA
CHF 642.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 4.6B
Profit Margin
45.20%
52 Week High
CHF 46.47
52 Week Low
CHF 27.22
Dividend
1.12%
Price / Book Value
2.36
Price / Earnings
-2.5K
Price / Tangible Book Value
-27.02
Enterprise Value
CHF 23.5B
Enterprise Value / EBITDA
33.49
Operating Income
CHF 245.0M
Return on Equity
0.06%
Return on Assets
0.81
Cash and Short Term Investments
CHF 701.0M
Debt
CHF 4.4B
Equity
CHF 8.4B
Revenue
CHF 10.1B
Unlevered FCF
CHF 1.8B
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium